01.12.2011
LUX-Head & Neck 1 is a randomised, open-label, Phase III study to evaluate the efficacy of oral afatinib* versus intravenous methotrexate in patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) who have progressed after platinum-based chemotherapy.